Price
42.65
+1.37%52W Range
Market Cap
₹353.93 Cr
Traded: ₹0.89 Cr (0.25%) 0.0x
Free Float: ₹108.05 Cr (0.83% of FF traded)
Volume · 60D trend
2.1 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +12.0% | +11.0% | +14.0% | -- | +37.0% | Accelerating |
| ROE | +14.0% | +17.0% | +18.0% | -- | -- | Accelerating |
| Return | -- | +49.0% | -18.0% | -7.0% | -- | Stable |
| Profit | +28.0% | +38.0% | +22.0% | -- | +30.0% | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 57 | 59 | 53 | 38 | 41 | 39 | 39 | 31 | 41 | 30 | 42 | 31 | 28 |
| Expenses | 66 | 50 | 54 | 50 | 35 | 35 | 36 | 37 | 28 | 37 | 27 | 39 | 29 | 25 |
| Operating Profit | 3 | 7 | 4 | 3 | 3 | 7 | 3 | 2 | 3 | 5 | 3 | 3 | 2 | 3 |
| OPM % | 4.8% | 12.6% | 7.4% | 5.2% | 7.4% | 16.1% | 7.9% | 6.1% | 9.2% | 11.3% | 9.2% | 7.3% | 7.8% | 11.3% |
| Other Income | 1 | 3 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 3 | 8 | 4 | 3 | 2 | 6 | 4 | 2 | 2 | 4 | 2 | 3 | 2 | 2 |
| Tax % | 24.6% | 29.7% | 25.1% | 25.9% | 25.5% | 23.9% | 25.1% | 27.2% | 27.1% | 26.9% | 30.1% | 22.6% | 29.6% | 22.5% |
| Net Profit | 3 | 6 | 3 | 3 | 2 | 4 | 3 | 2 | 2 | 3 | 1 | 2 | 1 | 2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.3 | 0.7 | 0.3 | 0.3 | 0.2 | 0.5 | 0.3 | 0.2 | 0.2 | 0.4 | 0.2 | 0.3 | 0.2 | 0.2 |
| Sales Growth (YoY) | 81.0% | 38.0% | 49.0% | 34.0% | 24.0% | 0.0% | 33.0% | -7.0% | -2.0% | 48.0% | -23.0% | 5.0% | -5.0% | -- |
| Sales Growth (QoQ) | -- | -3.2% | 11.5% | 37.6% | -7.4% | 4.6% | 0.4% | 27.8% | -25.5% | 38.8% | -29.7% | 34.6% | 12.4% | -- |
| OP Growth (YoY) | 17.0% | 7.4% | 39.2% | 13.3% | 0.0% | 43.2% | 13.9% | -21.5% | 14.6% | 46.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -53.8% | 65.1% | 58.6% | -3.2% | -57.7% | 114.1% | 29.0% | -14.5% | -39.4% | 70.3% | -11.1% | 24.8% | -22.4% | -- |
| Profit Growth (YoY) | 38.5% | 35.0% | 9.5% | 65.8% | 15.2% | 40.0% | 80.7% | -36.2% | 19.7% | 75.1% | -35.6% | -15.3% | 266.7% | -5.8% |
| EPS Growth (YoY) | -- | 36.5% | 9.4% | 63.2% | 15.8% | 40.5% | 88.2% | -34.5% | 18.8% | 76.2% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 102.9% | 12.9% | 40.9% | -57.7% | 62.5% | 68.4% | 0.0% | -48.6% | 117.7% | -41.4% | 81.3% | -23.8% | -- |
| OP Margin | -- | 12.6% | 7.4% | 5.2% | 7.4% | 16.1% | 7.9% | 6.1% | 9.2% | 11.3% | 9.2% | 7.3% | 7.8% | 11.3% |
| Net Margin | -- | 10.3% | 4.9% | 4.9% | 4.8% | 10.5% | 6.6% | 3.9% | 5.1% | 7.5% | 4.9% | 5.7% | 4.2% | 6.3% |
| Material Cost % | 80.0% | 69.0% | 75.0% | 77.0% | 71.0% | 66.0% | 73.0% | 77.0% | 72.0% | 74.0% | 72.0% | 80.0% | 76.0% | 72.0% |
| Employee Cost % | 3.0% | 3.0% | 4.0% | 3.0% | 4.0% | 4.0% | 5.0% | 4.0% | 5.0% | 3.0% | 6.0% | 3.0% | 4.0% | 5.0% |
| P/S | 1.49 | 1.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 25.54 | 30.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.66 | 5.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed
Please find enclosed outcome
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve 1. To consider and approve, ....
Please find enclosed
Please find enclosed
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held ....
Please find enclosed
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve 1. Audited Financial Results ....
Please find enclosed
Please find enclosed
Please find enclosed
Please find enclosed
Please find attached Quarterly Financial Results for the quarter ended 31st December 2025
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held ....
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve 1. Unaudited Financial Results ....
Please find attached requisite disclosure
Please find attached Intimation under Regulation 30 of SEBI LODR Regulations 2025
Please find enclosed disclosure with regards to closure of trading window
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held ....
The Company has secured government supply order from the Country of Dominican Republic
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve We hereby inform you that the ....
Please find annexure
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shweta Harshit Mehta & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Harshit Haresh Mehta & PACs
Please find attached disclosure for Closure of Trading Window
Please find attached Intimation under Regulation 30 under SEBI LODR Regulations 2015
Please find attached Proceedings of 31st AGM
Please find attached intimation
Please find attached copy of Newpaper Publication
Please find attached Intimation of resignation of Mr. Hasan Bohra as Company Secretary & Compliance Officer.
Please find attached Financial results for June, 2025
Please find attached Outcome of Board Meeting held today
Please find attached Copy of Newspaper Publication.
Please find attached Intimation of Book Closure of the Company.
Please find attached Notice alongwith 31st Annual Report of the Company.
Please find attached Annual Report of the Company for the FY 2024-25.
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 ,inter alia, to consider and approve Unaudited Financial Results ....
Please find attached Copy of Newspaper Publication.
Please find attached Outcome of Meeting held today.
Please find attached Outcome of Board Meeting held today for the following: 1. Re-appointment of Mr. Harshit Mehta as Managing Director 2. Continuation of Directorship of Mr. Haresh ....
Please find attached Outcome of Board Meeting held today
Please find attached Intimation of Closure of Trading Window.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Haresh Kapurlal Mehta & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rita Haresh Mehta
The Company is pleased to announce commencement of work for New Factory.
Please find attached Copy of Newspaper Publication
Please find attached Intimation for Cessation of Term of VJ Shah & Co as Statutory Auditors of the Company.
Please find attached Intimation for appointment of Mr. Haresh Sanghvi as Secretarial Auditor and approval of Director''s Report alongwith Annexures.
Please find attached Financial Results for quarter and year ended 31st March, 2025.
Annual Reports
8Credit Ratings
3